(Q34434145)

English

A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

F Joel Leong

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Rong Zhao

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Shuqi Zeng

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Baldur Magnusson

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Thierry T Diagana

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Peter Pertel

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

18 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

6437-6443

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Spiroindolone KAE609 for falciparum and vivax malaria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Spiroindolone that inhibits PfATPase4 is a potent, cidal inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Antimalarial drug discovery - approaches and progress towards new medicines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

The need for new antimalarial drugs less prone to resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Mechanistic study of the spiroindolones: a new class of antimalarials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Imidazolopiperazines: lead optimization of the second-generation antimalarial agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

The threat of artemisinin-resistant malaria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Imidazolopiperazines: hit to lead optimization of new antimalarial agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Artemisinin Resistance in Plasmodium falciparum Malaria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

6 July 2018

Artemisinin resistance is a clear and present danger

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4249437

27 October 2018

Identifiers

10.1128/AAC.03478-14

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34434145&oldid=1550535391"